Product logins

Find logins to all Clarivate products below.


Bispecific Therapies – Special Topics – Special Topics: Bispecific Therapies (G7 and China)

Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve target specificity. These therapies can be designed to recruit and activate immune cells, interfere with receptor signaling, and inactivate signaling ligand. Drug manufacturers are extensively exploring bispecific therapies either as monotherapy or in combination with other targeted immunotherapies. To date, six bispecific therapies have been approved across the G7 and China, for both hematological malignancies and solid tumors. This Special Topics report provides a comprehensive view of the current bispecific therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development across a range of oncology indications.

QUESTIONS ANSWERED

  • What is the current landscape for approved bispecific therapies? What are the key trends? What impact will these treatments have in their respective oncology indications?
  • What does the bispecific therapy pipeline look like by phase of development? What are the key classes of therapies? What are the key developers? In which geographies is development focused?
  • What are the trends in the development of bispecific therapies? In which oncology indications most bispecific therapies are being investigated? What are the key targets in solid and hematological tumors?

GEOGRAPHIES

United States, EU5, Japan, and China

PRIMARY AND SECONDARY MARKET RESEARCH

In-depth interviews with six key opinion leaders (hematologist-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases (Cortellis, ClinicalTrials.gov); industry / scientific conferences; news; media

KEY DRUGS COVERED

Blincyto, Kadulini, Kimmtrak, Lunsumio, Rybrevant, and Tecvayli

EMERGING THERAPIES

Therapies in Phase III development (e.g., glofitamab, elranatamab, epcoritamab)

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the bispecific therapy landscape in relevant oncology indications.

Related Market Assessment Reports

Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…